Alnylam Pharmaceuticals Inc (ALNY)

NASDAQ
Currency in USD
270.19
+19.04(+7.58%)
Closed·
After Hours
272.00+1.81(+0.67%)
·
ALNY Scorecard
Full Analysis
Net income is expected to grow this year
ALNY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
252.79270.20
52 wk Range
144.73304.39
Key Statistics
Edit
Prev. Close
270.19
Open
255.48
Day's Range
252.79-270.2
52 wk Range
144.73-304.39
Volume
1.25M
Average Volume (3m)
989.3K
1-Year Change
79.56%
Book Value / Share
0.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALNY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
320.56
Upside
+18.64%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings upwards for the upcoming period
Show more

Alnylam Pharmaceuticals Inc Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer’s disease; and ALN-HTT02 that is in phase I clinical trial for Huntington’s disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Employees
2230

Alnylam Pharmaceuticals Inc SWOT Analysis


RNAi Pionee
Alnylam leads in RNA interference therapeutics, with Amvuttra poised to enter the $5-6 billion ATTR-CM market, showcasing strong revenue growth and nearing profitability.
Amvuttra's Potential
Explore Amvuttra's impressive HELIOS-B trial results and its potential to become a first-line therapy for ATTR-CM, with approval anticipated by April 2025.
Market Dynamics
Delve into Alnylam's competitive landscape, including challenges from oral therapies and strategies to leverage its established commercial infrastructure in rare diseases.
Analyst Outlook
Learn about Alnylam's diverse analyst ratings, with price targets ranging from $205 to $329, reflecting varied perspectives on the company's growth potential.
Read full SWOT analysis

Alnylam Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of -0.01 beat forecast of -0.93; revenue of $594.19M exceeded expectations of $588.75M
  • Revenue grew 28% YoY; TTR franchise up 36% to $359M; rare disease franchise up 8% to $109M
  • Stock fell 3.89% despite earnings beat; company maintains $2.6B cash and equivalents
  • 36% YoY growth projected for TTR franchise; TRITON Centimeters Phase III study to start in H1 2025
  • CEO reports strong start to 2025; CCO notes 80% of global addressable population remains untreated
Last Updated: 2025/05/01, 15:46
Read Full Transcript

Compare ALNY to Peers and Sector

Metrics to compare
ALNY
Peers
Sector
Relationship
P/E Ratio
−130.6x−4.4x−0.5x
PEG Ratio
−5.98−0.130.00
Price/Book
305.2x1.5x2.6x
Price / LTM Sales
15.0x3.8x2.9x
Upside (Analyst Target)
27.8%122.1%53.0%
Fair Value Upside
Unlock16.4%8.9%Unlock

Analyst Ratings

24 Buy
8 Hold
1 Sell
Ratings:
33 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 320.56
(+18.64% Upside)

Earnings

Latest Release
May 01, 2025
EPS / Forecast
-0.01 / -0.93
Revenue / Forecast
594.19M / 588.75M
EPS Revisions
Last 90 days

FAQ

What Is the Alnylam (ALNY) Stock Price Today?

The Alnylam stock price today is 270.19

What Stock Exchange Does Alnylam Trade On?

Alnylam is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Alnylam?

The stock symbol for Alnylam is "ALNY."

What Is the Alnylam Market Cap?

As of today, Alnylam market cap is 35.23B.

What Is Alnylam's Earnings Per Share (TTM)?

The Alnylam EPS (TTM) is -2.10.

When Is the Next Alnylam Earnings Date?

Alnylam will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is ALNY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.